NasdaqCM · Biotechnology

Corbus Pharmaceuticals (CRBP)

Stock, pipeline and biotech catalyst intelligence

Analyst view

Strong Buy+232.6%

$34.52 average target

$10.38+0.54 (+5.5%)Latest market snapshot · Yahoo Finance

Market cap$200.8M

Cash$117.9M

Quarterly burn$29.6M

Pipeline assets7

Short float14.2%

Clinical portfolio

Corbus Pharmaceuticals Drug Pipeline

Showing 1 of 7

Asset	Indication	Stage	Milestone	Signals ?
CRB-913	Obesity	Phase 1b	Sep 30, 2026	Mgmt interest

Continue with BioPharma ProUnlock 6 additional programs and complete development details.

Unlock Pro

Upcoming milestones

CRBP Catalyst Timeline

1 currently tracked

Sep 30, 2026

CRB-913

Phase 1bMgmt interest

Obesity

Company profile

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.

Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.